28
nanotimes
Companies Facts
for enabling computer chips to communicate using pulses of light instead of electrical signals, which can deliver increased performance of computing systems.
http://www.youtube.com/watch?v=WBkvzubVyOY
I
llumina, Inc. (NASDAQ: ILMN) announced MiSeq™, a low-cost personal sequencing system that pro-
vides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Leveraging the company‘s TruSeq™ sequencing chemistry, the system‘s revo- lutionary workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day. Expected to be priced under $125,000 with individual run prices ranging from $400-$750, MiSeq will be the most affordable next- generation sequencing (NGS) platform available. Illumina expects to take initial orders for the MiSeq™ platform starting in April 2011 and anticipates ship- ping the first commercial units of MiSeq in summer 2011.
Furthermore, Illumina has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. A key component of the acquisition is direct access to Epicentre‘s proprietary Nextera™ technology for next-generation sequencing library preparation, which greatly simplifies genetic analysis workflows and reduces time from sample preparation to an- swer.
Illumina announced preliminary revenue for the fourth quarter of 2010 of approximately $260 milli- on. This implies fiscal year 2010 revenue of appro-
ximately $901 million or annual growth of 35%. The Company also announced preliminary non-GAAP earnings per share for the fourth quarter and fiscal year 2010 between $0.28 and $0.29 and $1.05 and $1.06, respectively. The Company expects revenue growth for the full year 2011 of approximately 20% from anticipated 2010 revenue of $901 million and non-GAAP earnings per share to grow more than 30% from anticipated 2010 non-GAAP earnings per share between $1.05 and $1.06.
http://www.illumina.com/miseq
I
nhibOx Ltd, based in Oxford, U.K., the specialist in novel and effective computational methods for
drug discovery, launched Scopius-5 – the world‘s largest currently available drug discovery scree- ning database and the first system to pass 100 milli- on compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.
The Scopius-5 database platform stores many details of selected compounds, invaluable to those working in drug discovery. They include: multiple-conformati- on 3D models, shape and charge descriptors, pro- perty values and compound availability information, and/or synthetic route details. To ensure their useful- ness in discovery projects, entries are filtered against a set of drug-likeness criteria - structural and physical properties known to be common to almost all phar- maceutical compounds.
Scopius-5 consists of more than 110 million entries in three distinct sections, each enabling different approaches to lead identification and optimization studies. Scopius-5 is able to support very large-scale virtual screening studies at practical speeds because
11-01 :: December 2010 / January 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95